PPF Group

Mobi Banka is a pioneering digital banking institution based in Serbia that caters to both retail and corporate customers. It offers a fully mobile banking platform, allowing users to manage their financial affairs interactively via their mobile phones or computers, providing complete control over funds and transactions. The bank's services include an overdraft facility, dinar term deposits, cash and device loans, and a mobile banking facility, all designed to enable customers to handle their finances conveniently without the constraints of traditional banking hours or extensive documentation. By prioritizing accessibility and innovation, Mobi Banka transforms the banking experience to meet the demands of a modern, mobile-oriented clientele.

FlashPack Ltd is a London-based travel agency that specializes in providing travel, tour, transportation, and accommodation services to both the general public and commercial clients. Established in 2013, the company offers a diverse range of travel experiences including beach holidays, city breaks, wellness retreats, wildlife excursions, and adventure trips tailored for middle-aged solo travelers. FlashPack focuses on fostering meaningful connections among travelers through group dynamics, enabling individuals to find companions for their journeys. The company aims to create memorable experiences while ensuring a social atmosphere for those venturing out on their own.

InPost operates as a pan-European provider of automated parcel machines and an out-of-home delivery platform for e-commerce. Its network spans nine countries—Poland, France, the United Kingdom, Spain, Portugal, Italy, the Netherlands, Belgium, and Luxembourg—supporting the entire e-commerce value chain and enhancing delivery experiences for merchants and consumers. The company specializes in out-of-home solutions that improve access and convenience, underscoring a commitment to innovation and service quality within the European logistics landscape.

ProSiebenSat.1 Media SE, established in 2000, is a prominent German mass media company. It operates 15 television stations across Germany, Austria, and Switzerland, reaching approximately 42 million households in Europe. The company's portfolio also includes radio stations and print businesses. ProSiebenSat.1 Digital, a subsidiary, focuses on new media services. The company is headquartered in Unterföhring, Germany.

ClearBank Ltd. is a financial institution based in the United Kingdom that specializes in providing banking services to financial service providers. Founded in 2015, ClearBank operates a clearing and agency banking platform that facilitates real-time clearance of payment transactions. The company offers a range of services including account management, liquidity management, and transaction analysis, enabling clients to make transactions quickly and efficiently. By improving access to various payment schemes, ClearBank aims to enhance the overall banking experience for its clients, which include commercial businesses and individual consumers.

Sotio is an international biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases. As part of the PPF Group, it aims to build a diverse biotechnology portfolio through its own research and development efforts, as well as collaborations, investments, and mergers. The company is advancing a proprietary platform of active cellular immunotherapy based on dendritic cells, which is its most developed project. Sotio also has a robust clinical pipeline that includes a differentiated superagonist targeting IL-15, a proprietary technology to enhance CAR T therapy efficacy, and a new generation of stable antibody-drug conjugates. Through these initiatives, Sotio seeks to translate scientific advancements into tangible benefits for patients.

Navigare Yachting specializes in premium yacht charter services, catering primarily to sailing enthusiasts. The company offers a diverse fleet of new or pre-owned sailing yachts, with options for crewed or bareboat charters. Additionally, they provide related services such as sailboat brokerage and investment opportunities. By combining the efficiency of a larger fleet with local expertise from various countries, Navigare Yachting aims to deliver an optimized and enjoyable charter experience for clients seeking to share their passion for sailing with family and friends.

Culture Trip Ltd. is a London-based company founded in 2011 that operates a platform for local content creators to share diverse cultural content through articles, videos, photography, and other media. The platform encompasses various topics, including art, travel, food, music, and technology, allowing contributors such as writers, filmmakers, and photographers to publish their insights. In addition to providing in-house articles, Culture Trip offers a mobile application that delivers personalized travel recommendations and curated experiences. The company has expanded its offerings to include immersive, small-group travel adventures, led by local insiders, which aim to provide authentic, off-the-beaten-path experiences. With a focus on sustainability, Culture Trip is working towards becoming a carbon neutral travel company, emphasizing the importance of connecting travelers to the culture and people of the destinations they visit. The company also maintains offices in New York and Tel Aviv, further supporting its global reach and community engagement.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

Central European Media Enterprises Ltd. (CME) is a media and entertainment company that operates broadcast, content, and new media businesses in Central and Eastern Europe. With a presence in countries like Bulgaria, Croatia, the Czech Republic, Romania, the Slovak Republic, and Slovenia, CME's broadcast segment includes 36 television channels that reach approximately 50 million viewers. The company's Media Pro Entertainment division focuses on production and distribution, while its New Media segment includes over 70 websites and a video-on-demand service called Voyo. Overall, CME plays a significant role in delivering diverse entertainment content to audiences across the region.

MaveriX Oncology is a biotechnology company dedicated to the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies. The company focuses on innovative immunotherapy solutions that address the therapeutic gaps in cancer treatment. By leveraging unexploited insights into cancer and immune cell metabolism within the tumor microenvironment, which are common across various cancers, MaveriX enables the selective delivery of chemotherapy's tumor cell-killing effects while simultaneously generating a robust immune response. This approach aims to enhance treatment efficacy and broaden the potential for combating a wide range of cancers.

Autolus Therapeutics is a biopharmaceutical company based in London, England, focused on developing next-generation programmed T cell therapies for cancer treatment. Founded in 2014 by Tim Funnell and Martin Pule, the company has established a clinical-stage pipeline that includes several innovative therapies, such as Obe-cel (obecabtagene autoleucel) and others designated as AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Through its research and development efforts, Autolus aims to advance the field of cancer immunotherapy and improve outcomes for patients battling various types of cancer.

ClearBank Ltd. is a financial institution based in the United Kingdom that specializes in providing banking services to financial service providers. Founded in 2015, ClearBank operates a clearing and agency banking platform that facilitates real-time clearance of payment transactions. The company offers a range of services including account management, liquidity management, and transaction analysis, enabling clients to make transactions quickly and efficiently. By improving access to various payment schemes, ClearBank aims to enhance the overall banking experience for its clients, which include commercial businesses and individual consumers.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Culture Trip Ltd. is a London-based company founded in 2011 that operates a platform for local content creators to share diverse cultural content through articles, videos, photography, and other media. The platform encompasses various topics, including art, travel, food, music, and technology, allowing contributors such as writers, filmmakers, and photographers to publish their insights. In addition to providing in-house articles, Culture Trip offers a mobile application that delivers personalized travel recommendations and curated experiences. The company has expanded its offerings to include immersive, small-group travel adventures, led by local insiders, which aim to provide authentic, off-the-beaten-path experiences. With a focus on sustainability, Culture Trip is working towards becoming a carbon neutral travel company, emphasizing the importance of connecting travelers to the culture and people of the destinations they visit. The company also maintains offices in New York and Tel Aviv, further supporting its global reach and community engagement.

Škoda Transportation is a manufacturer of vehicles for railways and public transport.

ClearBank Ltd. is a financial institution based in the United Kingdom that specializes in providing banking services to financial service providers. Founded in 2015, ClearBank operates a clearing and agency banking platform that facilitates real-time clearance of payment transactions. The company offers a range of services including account management, liquidity management, and transaction analysis, enabling clients to make transactions quickly and efficiently. By improving access to various payment schemes, ClearBank aims to enhance the overall banking experience for its clients, which include commercial businesses and individual consumers.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Culture Trip Ltd. is a London-based company founded in 2011 that operates a platform for local content creators to share diverse cultural content through articles, videos, photography, and other media. The platform encompasses various topics, including art, travel, food, music, and technology, allowing contributors such as writers, filmmakers, and photographers to publish their insights. In addition to providing in-house articles, Culture Trip offers a mobile application that delivers personalized travel recommendations and curated experiences. The company has expanded its offerings to include immersive, small-group travel adventures, led by local insiders, which aim to provide authentic, off-the-beaten-path experiences. With a focus on sustainability, Culture Trip is working towards becoming a carbon neutral travel company, emphasizing the importance of connecting travelers to the culture and people of the destinations they visit. The company also maintains offices in New York and Tel Aviv, further supporting its global reach and community engagement.

CytunePharma is a private company based in France that focuses on the research and development of novel immunotherapeutic agents, primarily targeting cancer. Founded in 2007, the company leverages a proprietary scientific breakthrough in immunology involving the trans-presentation mechanism of interleukin-15, a critical immune factor. Its lead compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector, enhancing the effectiveness of immune responses. CytunePharma is also working on conjugated monoclonal antibodies that are linked to CYP 0150, expanding its portfolio of therapeutic options. The company is managed by Dr. David Bechard, a seasoned biotech entrepreneur, and Dr. Yannick Jacques, who serves as the Director of Public Research at the French National Institute for Health and Medical Research.

ClearBank Ltd. is a financial institution based in the United Kingdom that specializes in providing banking services to financial service providers. Founded in 2015, ClearBank operates a clearing and agency banking platform that facilitates real-time clearance of payment transactions. The company offers a range of services including account management, liquidity management, and transaction analysis, enabling clients to make transactions quickly and efficiently. By improving access to various payment schemes, ClearBank aims to enhance the overall banking experience for its clients, which include commercial businesses and individual consumers.

CytunePharma is a private company based in France that focuses on the research and development of novel immunotherapeutic agents, primarily targeting cancer. Founded in 2007, the company leverages a proprietary scientific breakthrough in immunology involving the trans-presentation mechanism of interleukin-15, a critical immune factor. Its lead compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector, enhancing the effectiveness of immune responses. CytunePharma is also working on conjugated monoclonal antibodies that are linked to CYP 0150, expanding its portfolio of therapeutic options. The company is managed by Dr. David Bechard, a seasoned biotech entrepreneur, and Dr. Yannick Jacques, who serves as the Director of Public Research at the French National Institute for Health and Medical Research.